BTK and cancer: 22.0405.aF demonstrated an additive effect in cell killing in the presence of venetoclax or ibrutinib (Figures 3B, C), thus supporting that the addition of 22.0405.aF to current treatment paradigms may yield stronger clinical responses in patients with cancer treated with BTK inhibitors or venetoclax.